Kelly Esposito
Primary Care · Saint Louis, MONPI 1154862225
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$814
- Takeda Pharmaceuticals U.S.A., Inc.$625
- Regeneron Healthcare Solutions, Inc.$595
- Sanofi$590
- Novartis$356
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,147100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,132 |
| AstraZeneca | 38 | $814 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $625 |
| Regeneron Healthcare Solutions, Inc. | 20 | $595 |
| Sanofi | 27 | $590 |
| Novartis | 18 | $356 |
| CSL Behring | 11 | $290 |
| Pharming Healthcare, Inc. | 10 | $239 |
| Pfizer | 10 | $175 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $171 |
| Amgen | 8 | $168 |
| Optinose US, Inc. | 8 | $136 |
| AbbVie | 6 | $132 |
| Kaleo, Inc. | 7 | $100 |
| Mylan Specialty L.p. | 5 | $90 |
| Boehringer Ingelheim | 4 | $89 |
| Octapharma USA, Inc. | 1 | $70 |
| Lilly USA, LLC | 3 | $65 |
| Genentech USA, Inc. | 2 | $46 |
| Grifols USA, LLC | 2 | $40 |
| Merck | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Biocryst US Sales Co., LLC | 1 | $25 |
| LEO Pharma Inc. | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| GC Biopharma USA, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Organon | 3 | $13 |
| Phadia US Inc. | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$109
How this compares
$6,173 in reported general payments places this provider in the 95th percentile of 106 primary care providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $44,456 |
| EliquisApixaban | 29 | $39,763 |
| OzempicSemaglutide | 30 | $31,907 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $24,818 |
| Spiriva RespimatTiotropium Bromide | 14 | $15,362 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,682 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,455 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 16 | $4,435 |
| PaxlovidNirmatrelvir/Ritonavir | 22 | $4,287 |
| Ipratropium Bromide | 112 | $3,346 |
| Epinephrine | 16 | $2,595 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,505 |
| Ventolin HfaAlbuterol Sulfate | 12 | $949 |
| Cefdinir | 40 | $926 |
| Rosuvastatin Calcium | 97 | $891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Arexvy | $1,132 | $79,390109 claims |
| PfizerEliquis, Paxlovid | $175 | $44,05051 claims |
| Novo NordiskOzempic | $20 | $31,90730 claims |
| Boehringer IngelheimSpiriva Respimat | $89 | $15,36214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 primary care providers in Missouri.
Other primary care in Saint Louis
- Joy MurphySaint Louis$7K
- Elizabeth YoungSaint Louis$5K
- Heather BealSaint Louis$4K
- Ashley TitchenalSaint Louis$3K
- Brittany ShoultsSaint Louis$3K
- Stella HeineSaint Louis$2K
- Johnathan WieseSaint Louis$2K
- Taylor RouserSaint Louis$2K
- Faye MonahanSaint Louis$1K
- Alita BillopsSaint Louis$840
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.